The true disruptor is Tirzepatide, the world's first GIP/GLP-1 dual receptor agonist. In the SURPASS series of trials, it reduced glycated hemoglobin by up to 2.4% and body weight by up to 11.3kg, far exceeding single target drugs. Retarutide, which was approved in 2024, has expanded its targets to three (GLP-1+GIP+glucagon) and achieved an average weight loss of 24.2% in phase II trials, approaching the effect of weight loss surgery.
We provide GLP-1, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/api-researching-only/glp-1-7-37-peptide.html
Xingrui Pharmaceutical has completed nearly $40 million in Series B+financing to deepen its focus on mRNA innovative therapies
Recently, Starna Therapeutics announced the completion of nearly $40 million in Series B+funding, which is jointly invested by well-known industry funds, Hillhouse Capital, IYFECapital, LAV Asia Fund, Sherpa Investment, Source Code Capital, and Chunhua Capital.
After completing a Series B financing of $44 million, the company has once again received support from well-known institutions after half a year. The funds from this tomb collection will be focused on accelerating the clinical development process of multiple pipelines for in vivo CAR-T cell therapy, promoting the construction of extrahepatic delivery platforms such as the lungs, intestines, and nervous system, and consolidating and strengthening the company's innovative research and development layout in the field of mRNA therapy.
Zhengda Tianqing joins hands with GSK! The first AS0 drug Bepirovirsen accelerates the functional cure of hepatitis B
On May 11, 2026, China Biopharmaceutical (1177. HK) officially announced that the core enterprise Zhengda Tianqing and GlaxoSmithKline (GSK) have reached an exclusive strategic cooperation, which will accelerate the marketing process of the same kind of pioneering (FIC) new drug Bepirovirsen in China. At the beginning of this year, Bepirovirsen has submitted an application for marketing to the Drug Evaluation Center (CDE) of the National Drug Administration, and has been included in the list of priority evaluation varieties. It is expected to become the first drug to achieve the functional cure of chronic hepatitis B, bringing a revolutionary breakthrough in the domestic hepatitis B treatment field.
According to the terms of the agreement, CP Tianqing will be responsible for the import, distribution, hospital access, promotion, and non promotion activities of Bepirovesen in mainland China. All sales revenue generated from this product will be recognized as CP Tianqing's operating revenue. GSK will continue to serve as the Marketing Authorization Holder (MAH) for drugs, responsible for overseeing registration affairs, quality control, drug vigilance, and global medical strategies. Both parties will also have the opportunity to further explore cooperation on the R&D pipeline assets of our group that are seeking cooperation opportunities in markets outside of China. This cooperation will support both parties in establishing a long-term partnership and provide a solid foundation for further expanding innovation asset cooperation in the future.
The functional cure rate with statistical and clinical significance supports the submission of marketing applications.
Use
Central suppression of appetite. GLP-1 can cross the blood-brain barrier and act on POMC neurons and AgRP neurons in the hypothalamic arcuate nucleus. The former releases alpha MSH to produce satiety signals, while the latter releases NPY/AgRP to produce hunger signals. GLP-1 activates the former and inhibits the latter, issuing the command 'I am full' from the central nervous system, reducing food intake at the root. Clinical data shows that semaglutide can reduce the average daily calorie intake of subjects by about 35%.
Multi organ protection. Recent studies have revealed that the role of GLP-1 goes far beyond metabolic regulation. In the field of cardiovascular diseases, large-scale clinical trials such as LEADER and SUSTAIN-6 have confirmed that liraglutide and semaglutide can reduce the risk of major adverse cardiovascular events (MACE) by 13% -26%. In the field of kidney disease, the FLOW test showed that semaglutide can reduce the risk of kidney disease progression by 24%. In the field of neuroscience, multiple observational studies suggest that GLP-1RA may reduce the risk of developing Alzheimer's and Parkinson's diseases. An observational study covering over 12000 people also found that individuals who use GLP-1 agonists for a long time have a significantly reduced probability of requiring surgery for inflammatory bowel disease.
